Myeloproliferative Neoplasms News

The combination of ruxolitinib and pegylated interferon alpha-2a exhibited encouraging activity among patients with myelofibrosis who had not previously received either drug, according to study results presented at ASH Annual Meeting and Exposition.

Hematopoietic stem cell transplant recipients of non-European ancestry had a significantly higher likelihood of receiving allogeneic grafts from HLA-mismatched donors than individuals of European ancestry, study results showed.

In this video, Srinivas K. Tantravahi, MBBS, MRCP(UK), discussed a case study, presented at the 14th International Congress on Myeloproliferative Neoplasms, of dizygotic twins.

Srinivas K. Tantravahi, MBBS, MRCP(UK), spoke with Healio about both nonpharmacologic interventions and pharmacologic developments for patients with myeloproliferative neoplasms.

In this video, Srinivas K. Tantravahi, MBBS, MRCP(UK), highlighted phase 2 data investigating hepcidin mimetics for polycythemia vera that appears to have eliminated the need for phlebotomy.

In this video, Brynn H. Parsegov, PA-C, highlighted two presentations from the 14th International Congress on Myeloproliferative Neoplasms.

Healio spoke with Brynn H. Parsegov, PA-C, about a presentation exploring the timing, as well as impact, of diagnosis for myeloproliferative neoplasms.

In this video, Brynn H. Parsegov, PA-C, discussed a case of fraternal female twins who sequentially presented with JAK2V617F mutation-positive myeloproliferative neoplasms.

In this video, Ann Mullally, MD, discussed her presentation investigating the use of therapeutic antibodies to target mutant calreticulin in myeloproliferative neoplasms.

John O. Mascarenhas, MD, spoke with Healio about takeaways from a presentation examining ways to optimize the currently available JAK2 inhibitors for the treatment of myelofibrosis.